Chemoinformaics analysis of ent-Zedoaronediol
| Molecular Weight | 252.354 | nRot | 0 |
| Heavy Atom Molecular Weight | 228.162 | nRig | 13 |
| Exact Molecular Weight | 252.173 | nRing | 2 |
| Solubility: LogS | -2.489 | nHRing | 0 |
| Solubility: LogP | 1.923 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 42 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 18 | No. of Aromatic Carbocycles | 0 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 2 |
| No. of Hydrogen atom | 24 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
| nHA | 3 | APOL | 43.459 |
| nHD | 2 | BPOL | 24.945 |
| QED | 0.65 |
| Synth | 4.403 |
| Natural Product Likeliness | 2.642 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.088 |
| Pgp-sub | 0.005 |
| HIA | 0.017 |
| CACO-2 | -4.602 |
| MDCK | 0.000017 |
| BBB | 0.965 |
| PPB | 0.599893 |
| VDSS | 0.582 |
| FU | 0.336615 |
| CYP1A2-inh | 0.027 |
| CYP1A2-sub | 0.474 |
| CYP2c19-inh | 0.068 |
| CYP2c19-sub | 0.869 |
| CYP2c9-inh | 0.025 |
| CYP2c9-sub | 0.164 |
| CYP2d6-inh | 0.016 |
| CYP2d6-sub | 0.248 |
| CYP3a4-inh | 0.04 |
| CYP3a4-sub | 0.617 |
| CL | 12.269 |
| T12 | 0.712 |
| hERG | 0.013 |
| Ames | 0.036 |
| ROA | 0.565 |
| SkinSen | 0.197 |
| Carcinogencity | 0.851 |
| EI | 0.037 |
| Respiratory | 0.62 |
| NR-Aromatase | 0.013 |
| Antiviral | Yes |
| Prediction | 0.891593 |